期刊文献+

四川省丙型肝炎患者HCV基因分型及基线HCV NS5A耐药突变位点分析 被引量:1

在线阅读 下载PDF
导出
摘要 目的 检测四川省丙型肝炎患者HCV基因分型及HCV NS5A耐药突变位点的分布特征。方法 收集2017年-2018年在四川省人民医院确诊的来自四川省的丙型肝炎患者160例,采集外周静脉血标本,使用Sanger测序法鉴定每一样本的HCV基因型及其亚型和HCV NS5A的基因序列。结果 160例丙型肝炎患者共测出1、2、3、6四种基因型和1b、2a、3a、3b、6a、6n六种基因亚型,其中以1b亚型检出率最高,占86.25%(138/160),其次为3b、6a亚型,均各占 3.75%(6/160),余下6n型占2.50%(4/160),2a、3a型均各占1.875%(3/160)。在HCV 1b亚型丙型肝炎患者在中,HCV NS5A基因耐药突变检出率为18.84%(26/138),其中以Y93H耐药突变率较高,占17.39%(24/138),其次L31M耐药突变率为1.45%(2/138)。结论 分析四川省丙型肝炎患者HCV基因型及HCV NS5A耐药突变位点的分布特点,可为该地区丙型肝炎患者基因型分布及耐药性研究和个体化抗病毒治疗提供指导依据。
出处 《肝脏》 2019年第8期917-918,共2页 Chinese Hepatology
作者简介 通信作者:杨兴祥.
  • 相关文献

参考文献2

二级参考文献10

  • 1D Alan Herbst,K Rajender Reddy.NS5A inhibitor, daclatasvir , for the treatment of chronic hepatitis C virus infection[J].Expert Opinion on Investigational Drugs.2013(10)
  • 2Jean-Michel Pawlotsky.NS5A inhibitors in the treatment of hepatitis C<!-- Doctopic: Review -->[J].Journal of Hepatology.2013(2)
  • 3Alessio Aghemo,Massimo Colombo.Selection of Resistant–Associated Variants to the NS5A Inhibitor Daclatasvir: Revenge of the Hepatitis C Virus[J].Gastroenterology.2013(1)
  • 4Min Gao.Antiviral activity and resistance of HCV NS5A replication complex inhibitors[J].Current Opinion in Virology.2013
  • 5Kelly A. Wong,Angela Worth,Ross Martin,Evguenia Svarovskaia,Diana M. Brainard,Eric Lawitz,Michael D. Miller,Hongmei Mo.Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885[J].Antimicrobial Agents and Chemotherapy.2013(12)
  • 6Dennis Hernandez,Nannan Zhou,Joseph Ueland,Aaron Monikowski,Fiona McPhee.Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors[J].Journal of Clinical Virology.2013(1)
  • 7Maria-Carlota Londo?o,Sabela Lens,Xavier Forns.Interferon free regimens for the “difficult-to-treat”: Are we there?[J].Journal of Hepatology.2013(4)
  • 8Lenore A. Pelosi,Stacey Voss,Mengping Liu,Min Gao,Julie A. Lemm.Effect on Hepatitis C Virus Replication of Combinations of Direct-Acting Antivirals, Including NS5A Inhibitor Daclatasvir[J].Antimicrobial Agents and Chemotherapy.2012(10)
  • 9Stanislas Pol,Reem H Ghalib,Vinod K Rustgi,Claudia Martorell,Greg T Everson,Harvey A Tatum,Christophe Hézode,Joseph K Lim,Jean-Pierre Bronowicki,Gary A Abrams,Norbert Br?u,David W Morris,Paul J Thuluvath,Robert W Reindollar,Philip D Yin,Ulysses Diva,Robert Hindes,Fiona McPhee,Dennis Hernandez,Megan Wind-Rotolo,Eric A Hughes,Steven Schnittman.Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial[J].The Lancet Infectious Diseases.2012(9)
  • 10Fumitaka Suzuki,Hitomi Sezaki,Norio Akuta,Yoshiyuki Suzuki,Yuya Seko,Yusuke Kawamura,Tetsuya Hosaka,Masahiro Kobayashi,Satoshi Saito,Yasuji Arase,Kenji Ikeda,Mariko Kobayashi,Rie Mineta,Sachiyo Watahiki,Yuzo Miyakawa,Hiromitsu Kumada.Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b[J].Journal of Clinical Virology.2012(4)

共引文献27

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部